As
previously disclosed, on June 6, 2018, Athersys, Inc. (“we” or the
“Company”), its wholly-owned subsidiary, ABT
Holding Company (together with the Company, “Athersys”), and HEALIOS
K.K. (“Healios”) entered into a Collaboration Expansion Agreement (the
“Collaboration Expansion Agreement”). Under the Collaboration Expansion
Agreement, among other things, Athersys granted to Healios an exclusive
right of first negotiation through September 1, 2018 (the “ROFN Period”)
with respect to an option for an exclusive license in China to develop
and commercialize
MultiStem products for the treatment of one or more of ischemic stroke,
acute respiratory distress syndrome, and either trauma or an alternative
indication mutually agreed upon. On August 31, 2018, Athersys and
Healios amended the Collaboration
Expansion Agreement to extend the ROFN Period through December 6, 2018,
and on December 6, 2018, the ROFN Period was further extended to
December 14, 2018. Additionally, on November 29, 2018, Athersys received
the third
$2.5 million payment under the terms of the Collaboration Expansion
Agreement.
Item 1.01. |
Entry into a Material Definitive Agreement. |